Should I buy Abbott Laboratories (ABT) stock or is it too late?
⭐ The most reliable of them, either direction: JP Morgan — 68% of its targets hit on this sector (364 calls tested). It aims for $120 (+17 %), call made on July 18, 2026, maturing on July 18, 2027 (88 d ago).
Firm-by-firm track record on Abbott Laboratories
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| JP Morgan | 89 % | +13.4 % | 9 | $120 +17% |
| UBS | 76 % | +9.2 % | 17 | $125 +22% |
| Jefferies | 81 % | +9.2 % | 27 | $145 +41% |
| Stifel | 75 % | +8.1 % | 20 | $120 +17% |
| Goldman Sachs | 60 % | +5.6 % | 5 | $113 +10% |
| Raymond James | 64 % | +5.6 % | 28 | $146 +42% |
| Barclays | 63 % | +5.3 % | 19 | $120 +17% |
| Wells Fargo | 54 % | +4.0 % | 26 | $112 +9% |
✅ Reasons to believe
- 100% of analysts rate it a buy (Buy consensus, 18 ratings) — a sign of market conviction.
- Median price target $120, i.e. +17% from the current price ($103).
- The most reliable firm on ABT, JP Morgan (89% hit rate, 9 scored calls), targets $120 (call made on July 17, 2026, maturing on July 17, 2027) (+17%) in its most recent call.
- 10 analysts rated reliable (≥55% hit rate, beat their sector) are bullish on the stock.
- Pays a dividend (2.6% yield), raised for 10 years — regular income on top of potential upside.
⚠️ Reasons to hesitate
- High valuation (P/E ~33): strong growth is already "priced in", leaving little room for error.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- A near-unanimous consensus leaves little room for positive surprise — a lot of optimism is already baked in.
The analyst consensus on ABT
Median target $120 (+17%) · 18 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Abbott Laboratories now?
We won't decide for you. The facts: 100% of analysts rate it a buy, median target $120 (+17%), and JP Morgan (most reliable on ABT, 89%) targets $120. Weigh that against valuation (P/E ~33). This is not personalized advice.
Is it too late to invest in Abbott Laboratories?
Not according to analysts: the median target ($120) is still +17% above the current price ($103) (most reliable on ABT: JP Morgan, 89%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Abbott Laboratories still worth investing in?
It depends on the gap between the price ($103) and its estimated value: analysts target $120 on median (+17%), with 100% buys (most reliable on ABT: JP Morgan, 89%). Cross-check with their real reliability on ABT and the cautions above. Information, not advice.
What's the main risk in buying ABT?
High valuation (P/E ~33): strong growth is already "priced in", leaving little room for error.
→ Go deeper: the full Abbott Laboratories profile (consensus, analyst reliability, price target, performance).